Regeneron is a biotechnology company with its headquarters in New York City. Their product portfolio includes Praluent, Eylea and Arcalyst. Regeneron is a key player in research and development including drug discovery, human antibody technologies and genomics. Regeneron scientists focus on discovering new drug targets and developing effective product candidates through the proprietary VelociSuite platform of genetic technologies. In 2015 Regeneron announced a new collaboration with Sanofi to develop immuno-oncology treatments with a plan to begin clinical trials in 2016.